Status:
ENROLLING_BY_INVITATION
The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK)
Lead Sponsor:
University Hospital Dubrava
Conditions:
Pseudophakic Bullous Keratopathy
Glaucoma
Eligibility:
All Genders
40-90 years
Brief Summary
The goal of this clinical trial is to learn if topical netarsudil/latanoprost works to treat pseudophakic bullous keratopathy in patients with glaucoma. The main questions it aims to answer are: Does...
Detailed Description
Patients with glaucoma and pseudophakic bullous keratopathy will be randomly divided in two groups. Group 1 will take topical netarsudil/latanoprost 1x daily for 3 months and group 2 will take topical...
Eligibility Criteria
Inclusion
- both sex,
- age between 40 and 90 years
- pseudophakic bullous keratopathy
- glaucoma
Exclusion
- other anterior segment pathology (corneal opacities);
- ocular surface inflammation
- retinal diseases affecting visual acuity
Key Trial Info
Start Date :
April 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06960629
Start Date
April 1 2025
End Date
October 1 2026
Last Update
May 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Dubrava
Zagreb, Croatia, Croatia, 10000